IROP
IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB
07/28/2026
Back to search
Official data from USPTO
MULTIGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MULTIGEN
ST13
US500000079404951Class
1, 5, 35, 42
Filing
79404951
Registration
8182066
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/28/2026
Trademark type
Word
Nice classes
1, 5, 35, 42
Filing date
07/09/2024
Registration date
03/24/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/24/2026
Last transaction
07/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
BE
Examiner
SWEENEY, MOLLY B
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Confo Therapeutics NV
Confo Therapeutics N.V.
Representatives
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Technical classification
Nice Classes
Class 1Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substancesantibodies for stabilization of proteinsall the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; chimeric proteins to measuretest and develop compounds and ligands binding to G protein-coupled receptors (GPCRs); none of the foregoing for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Class 5
chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteinssmall molecules and antibodies for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; veterinary productsantigens and reagents for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; none of the foregoing for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Class 35
Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management; none of the foregoing services for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Class 42
Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines; none of the foregoing services for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Publications
History of USPTO decisions and trademark events.
34 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/13/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/12/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/24/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/24/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/24/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/03/2026
PUBO
PUBLISHED FOR OPPOSITION
02/03/2026
GPNX
NOTIFICATION PROCESSED BY IB
01/29/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/28/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/14/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/13/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/06/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/05/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/27/2025
GNFR
FINAL REFUSAL E-MAILED
10/27/2025
CNFR
FINAL REFUSAL WRITTEN
10/27/2025
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
08/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/11/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/11/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/11/2025
RFNT
REFUSAL PROCESSED BY IB
02/22/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
02/14/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/06/2025
RFRR
REFUSAL PROCESSED BY MPU
02/06/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/31/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/01/2025
CNRT
NON-FINAL ACTION WRITTEN
12/31/2024
DOCK
ASSIGNED TO EXAMINER
12/30/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/27/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/27/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/26/2024
Continuous trademark protection
Get notified about every new filing that threatens MULTIGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.